TWI692484B - 針對ｐｄ-１之抗體分子及其用途 - Google Patents

針對ｐｄ-１之抗體分子及其用途 Download PDF

Info

Publication number
TWI692484B
TWI692484B TW104102472A TW104102472A TWI692484B TW I692484 B TWI692484 B TW I692484B TW 104102472 A TW104102472 A TW 104102472A TW 104102472 A TW104102472 A TW 104102472A TW I692484 B TWI692484 B TW I692484B
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
acid sequence
bap049
antibody molecule
Prior art date
Application number
TW104102472A
Other languages
English (en)
Chinese (zh)
Other versions
TW201536808A (zh
Inventor
高登 詹姆士 費里曼
阿爾玲 海倫 夏培
華特Ａ 布萊特爾
珍妮佛 瑪莉 瑪塔拉薩
佩頓 凱薩琳 安妮 莎巴透斯
懷文 張
喬哈德 喬翰 弗萊
Original Assignee
美商達納 法伯癌症協會
瑞士商諾華公司
哈佛大學校長及研究員協會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52463182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI692484(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商達納 法伯癌症協會, 瑞士商諾華公司, 哈佛大學校長及研究員協會 filed Critical 美商達納 法伯癌症協會
Publication of TW201536808A publication Critical patent/TW201536808A/zh
Application granted granted Critical
Publication of TWI692484B publication Critical patent/TWI692484B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
TW104102472A 2014-01-24 2015-01-23 針對ｐｄ-１之抗體分子及其用途 TWI692484B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461931512P 2014-01-24 2014-01-24
US61/931,512 2014-01-24
US201462059676P 2014-10-03 2014-10-03
US62/059,676 2014-10-03
US201462094834P 2014-12-19 2014-12-19
US62/094,834 2014-12-19

Publications (2)

Publication Number Publication Date
TW201536808A TW201536808A (zh) 2015-10-01
TWI692484B true TWI692484B (zh) 2020-05-01

Family

ID=52463182

Family Applications (3)

Application Number Title Priority Date Filing Date
TW109112287A TW202045549A (zh) 2014-01-24 2015-01-23 針對pd-1之抗體分子及其用途
TW104102472A TWI692484B (zh) 2014-01-24 2015-01-23 針對ｐｄ-１之抗體分子及其用途
TW110146013A TW202237655A (zh) 2014-01-24 2015-01-23 針對pd-1之抗體分子及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW109112287A TW202045549A (zh) 2014-01-24 2015-01-23 針對pd-1之抗體分子及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110146013A TW202237655A (zh) 2014-01-24 2015-01-23 針對pd-1之抗體分子及其用途

Country Status (35)

Country Link
US (5) US9683048B2 (enExample)
EP (2) EP3097121B1 (enExample)
JP (3) JP6521986B2 (enExample)
KR (1) KR102357621B1 (enExample)
CN (3) CN111909269A (enExample)
AU (2) AU2015209145B2 (enExample)
BR (1) BR112016015677A2 (enExample)
CA (1) CA2935423C (enExample)
CL (1) CL2016001723A1 (enExample)
CY (1) CY1121542T1 (enExample)
DK (1) DK3097121T3 (enExample)
EA (1) EA201691488A1 (enExample)
EC (1) ECSP16068976A (enExample)
ES (1) ES2716685T3 (enExample)
HR (1) HRP20190516T1 (enExample)
HU (1) HUE043363T2 (enExample)
IL (2) IL246382A0 (enExample)
JO (2) JOP20200094A1 (enExample)
LT (1) LT3097121T (enExample)
ME (1) ME03366B (enExample)
MX (2) MX375683B (enExample)
MY (1) MY184757A (enExample)
NZ (1) NZ721678A (enExample)
PE (1) PE20170255A1 (enExample)
PH (1) PH12016501456A1 (enExample)
PL (1) PL3097121T3 (enExample)
PT (1) PT3097121T (enExample)
RS (1) RS58535B1 (enExample)
SG (2) SG10201900002QA (enExample)
SI (1) SI3097121T1 (enExample)
TN (1) TN2016000272A1 (enExample)
TW (3) TW202045549A (enExample)
UA (1) UA122479C2 (enExample)
UY (1) UY35967A (enExample)
WO (1) WO2015112900A1 (enExample)

Families Citing this family (621)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709412B2 (en) * 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
WO2010106051A1 (en) * 2009-03-17 2010-09-23 Universite De La Mediterranee Btla antibodies and uses thereof
PT2415470T (pt) 2009-03-30 2016-08-31 Eisai R&D Man Co Ltd Composição de lipossomas
BRPI1012675A2 (pt) 2009-06-26 2016-04-05 Soricimed Biopharma Inc compostos e métodos para a detecção de cânceres expressando trpv-6 e liberação de fármacos
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
SG194701A1 (en) 2011-04-29 2013-12-30 Apexigen Inc Anti-cd40 antibodies and methods of use
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
MX353548B (es) 2011-11-29 2018-01-18 Ono Pharmaceutical Co Clorhidrato derivado de purinona.
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
ES2761406T3 (es) 2013-03-15 2020-05-19 G1 Therapeutics Inc Protección transitoria de células normales durante una quimioterapia
WO2014168941A1 (en) 2013-04-09 2014-10-16 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
ES2845609T3 (es) 2013-05-02 2021-07-27 Anaptysbio Inc Anticuerpos dirigidos contra muerte programada-1 (PD-1)
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
NZ715201A (en) 2013-08-01 2021-12-24 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CN114632158A (zh) 2013-11-07 2022-06-17 豪夫迈·罗氏有限公司 抗cd20抗体与btk抑制剂的组合疗法
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
PT3102605T (pt) 2014-02-04 2019-02-12 Pfizer Combinação de um antagonista da mp-1 e um inibidor do rfcev para o tratamento do cancro
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9394365B1 (en) * 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR102248804B1 (ko) 2014-03-12 2021-05-11 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
WO2017042633A2 (en) * 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
MX2016012779A (es) 2014-03-31 2017-04-27 Genentech Inc Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
EP3195168B1 (en) * 2014-07-31 2022-09-07 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
DK3183268T3 (da) 2014-08-19 2020-05-11 Univ Pennsylvania Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
SMT202200367T1 (it) 2014-08-28 2022-11-18 Eisai R&D Man Co Ltd Derivato di chinolina a elevata purezza e metodo per la produzione dello stesso
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
KR20210149228A (ko) 2014-09-17 2021-12-08 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
KR20170066546A (ko) * 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US10774388B2 (en) 2014-10-08 2020-09-15 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
CN106999582A (zh) 2014-11-13 2017-08-01 约翰·霍普金斯大学 检查点阻断和微卫星不稳定性
EA037590B1 (ru) 2014-11-25 2021-04-19 Бристол-Майерс Сквибб Компани Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации
RS62332B1 (sr) 2014-11-26 2021-10-29 Xencor Inc Heterodimerna antitela koja vezuju cd3 i cd20
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN107645957A (zh) * 2015-02-09 2018-01-30 辛塔制药公司 治疗癌症的hsp90抑制剂和pd‑1抑制剂的组合疗法
PT3258951T (pt) 2015-02-19 2020-08-18 Compugen Ltd Anticorpos anti-pvrig e métodos de utilização
CA2976325C (en) 2015-02-25 2023-07-04 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
KR102662228B1 (ko) * 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017018872A2 (pt) 2015-03-04 2018-05-29 Eisai R&D Man Co Ltd combinação de um antagonista pd-1 e eribulina para tratamento de câncer
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
EP3067062A1 (en) * 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
US11060150B2 (en) * 2015-03-17 2021-07-13 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating cancer
SG10201908269SA (en) * 2015-03-17 2019-10-30 Omniox Inc Modulation of tumor immunity by protein-mediated o2 delivery
TWI703984B (zh) * 2015-04-03 2020-09-11 英商阿斯特克斯治療有限公司 用於癌症治療之fgfr/pd-1組合療法
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
US11896614B2 (en) 2015-04-17 2024-02-13 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172494A2 (en) 2015-04-23 2016-10-27 The Johns Hopkins University Combination of immunotherapy with local chemotherapy for the treatment of malignancies
PT3298021T (pt) 2015-05-18 2019-08-05 Tolero Pharmaceuticals Inc Pró-fármacos de alvocidib possuindo biodisponibilidade aumentada
US20160347836A1 (en) * 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
RS63897B1 (sr) 2015-05-29 2023-02-28 Bristol Myers Squibb Co Antitela protiv ox40 i njihova primena
US9782410B2 (en) 2015-06-09 2017-10-10 Rexahn Pharmaceuticals, Inc. Fluorocyclopentenylcytosine methods of use
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
RS61532B1 (sr) * 2015-07-14 2021-04-29 Bristol Myers Squibb Co Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
BR112018000917A2 (pt) 2015-07-16 2018-09-11 Bioxcel Therapeutics Inc abordagem inovadora para o tratamento de câncer através da imunomodulação
SG10201912978PA (en) 2015-07-21 2020-02-27 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US20180222982A1 (en) * 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3316902A1 (en) * 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
CN108136003A (zh) * 2015-07-29 2018-06-08 诺华股份有限公司 抗pd-1和抗m-csf抗体在癌症治疗中的联合应用
RU2018105846A (ru) * 2015-07-29 2019-08-28 Новартис Аг Комбинация антагониста pd-1 с ингибитором egfr
ES2878188T3 (es) * 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
ES2898958T3 (es) 2015-07-30 2022-03-09 Macrogenics Inc Moléculas de unión a PD-1 y LAG-3 y métodos de uso de las mismas
WO2017025498A1 (en) * 2015-08-07 2017-02-16 Pieris Pharmaceuticals Gmbh Novel fusion polypeptide specific for lag-3 and pd-1
RS59688B1 (sr) 2015-08-11 2020-01-31 Novartis Ag 5-bromo-2,6-di-(1h-pirazol-1-il)pirimidin-4-amin za upotrebu pri lečenju raka
WO2017030956A1 (en) * 2015-08-14 2017-02-23 Agenus Inc. Method of inducing a t-cell response to phosphopeptides using nucleic acids encoding phosphopeptide mimetics
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
WO2017040660A1 (en) * 2015-08-31 2017-03-09 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
HK1257840A1 (zh) * 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
CN108780084B (zh) 2015-09-03 2022-07-22 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
US10894044B2 (en) * 2015-09-16 2021-01-19 Board Of Regents, The University Of Texas System Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
CN108289953B (zh) * 2015-09-29 2022-03-11 细胞基因公司 Pd-1结合蛋白及其使用方法
BR112018006547A2 (pt) * 2015-09-29 2018-12-11 Asia Biotech Pte. Ltd anticorpos de pd-1 e usos dos mesmos
IL258214B2 (en) 2015-10-02 2023-04-01 Symphogen As Antibodies - anti pd-1 and preparations
US12030942B2 (en) 2015-10-02 2024-07-09 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
RU2761115C1 (ru) 2015-10-02 2021-12-06 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, специфические в отношении костимуляторного tnf-рецептора
IL257110B (en) * 2015-10-02 2022-09-01 Hoffmann La Roche Bispecific antibodies specific against pd1 and tim3
CN105175544B (zh) * 2015-10-20 2021-04-09 安徽瀚海博兴生物技术有限公司 一种抗pd-1人源化单克隆抗体及其应用
WO2017079303A1 (en) * 2015-11-02 2017-05-11 The Cleveland Clinic Foundation Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
EP3973988A1 (en) 2015-11-04 2022-03-30 Duke University Combination therapy of immunotoxin and checkpoint inhibitor
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
SG10201911035QA (en) 2015-11-18 2020-01-30 Merck Sharp & Dohme Pd1 and/or lag3 binders
CA3004794A1 (en) * 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
CN108697794A (zh) * 2015-12-17 2018-10-23 诺华股份有限公司 C-met抑制剂和抗pd-1抗体分子的组合及其用途
JP2019506844A (ja) 2015-12-18 2019-03-14 ノバルティス アーゲー ＣＤ３２ｂを標的とする抗体およびその使用方法
EP4643874A2 (en) 2015-12-22 2025-11-05 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
PT3394103T (pt) 2015-12-22 2023-09-04 Regeneron Pharma Combinação de anticorpos anti-pd-1 e anticorpos biespecíj'icos anti-cd20/anti-cd3 para tratar cancro
US20190025310A1 (en) * 2015-12-29 2019-01-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting the survival time of patients suffering from a microsatellite unstable cancer
WO2017120591A1 (en) 2016-01-08 2017-07-13 Euclises Pharmaceuticals, Inc. Combination of a chromene compound and a second active agent
IL260218B2 (en) 2016-01-11 2023-04-01 Novartis Ag Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
EP3408296A1 (en) * 2016-01-27 2018-12-05 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US10822415B2 (en) * 2016-01-28 2020-11-03 Inserm (Institut National De La Santéet De La Recherche Médicale) Methods for enhancing the potency of the immune checkpoint inhibitors
CA3013554A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Targeted therapeutic agents and uses thereof
JP7014724B2 (ja) 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Ｆａｂ免疫グロブリンおよびその使用
US20190049453A1 (en) * 2016-02-09 2019-02-14 The General Hospital Corporation Classification and Treatment of Gastric Cancer
CN108883203A (zh) * 2016-02-12 2018-11-23 麦迪逊疫苗公司 癌症疗法
CU20180088A7 (es) 2016-02-17 2019-05-03 Novartis Ag Anticuerpos anti tgfbeta 2
US20200281973A1 (en) 2016-03-04 2020-09-10 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
AU2017228474C1 (en) 2016-03-04 2024-03-28 Abmuno Therapeutics Llc Antibodies to TIGIT
WO2017175200A1 (en) * 2016-04-08 2017-10-12 The Regents Of The University Of California Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents
US11353459B2 (en) * 2016-04-14 2022-06-07 Creatv Microtech, Inc. Methods of using PD-L1 expression in treatment decisions for cancer therapy
EP3449921B1 (en) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin for inhibiting tumor growth
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN109689087B (zh) 2016-05-13 2023-04-04 奥里尼斯生物科学私人有限公司 靶向性突变干扰素-β及其用途
WO2017194782A2 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
TWI755395B (zh) * 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
WO2017201281A1 (en) * 2016-05-18 2017-11-23 Mayo Foundation For Medical Education And Research Targeting pd-l1 on tumor cells
HRP20230864T1 (hr) 2016-06-02 2023-11-10 Bristol-Myers Squibb Company Pd-1 blokada nivolumabom kod refraktornog hodgkinovog limfoma
KR20230119265A (ko) 2016-06-02 2023-08-16 브리스톨-마이어스 스큅 컴퍼니 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1항체의 용도
KR20190015407A (ko) 2016-06-03 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
KR20190015408A (ko) 2016-06-03 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
WO2017210637A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
BR112018075371A2 (pt) * 2016-06-10 2019-03-19 Novartis Ag usos terapêuticos de um inibidor de c-raf
IL263542B2 (en) * 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN116903741A (zh) 2016-06-20 2023-10-20 科马布有限公司 特异性结合于pd-l1的抗体或其抗原结合片段及其用途
CA3027911A1 (en) * 2016-06-30 2018-01-04 Nant Holdings Ip, Llc Coordinated treatment regimen to treat a tumor
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
AU2017293423B2 (en) 2016-07-05 2023-05-25 Beone Medicines I Gmbh Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
CN110214150A (zh) * 2016-07-28 2019-09-06 诺华股份有限公司 嵌合抗原受体和pd-1抑制剂的组合疗法
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
CN117736325A (zh) 2016-08-09 2024-03-22 科马布有限公司 分离抗体及其应用
EP3496707A4 (en) * 2016-08-09 2020-03-25 Angimmune, LLC Treatment of cancer using a combination of immunomodulation and check point inhibitors
AU2017313085B2 (en) 2016-08-19 2024-06-20 Beone Medicines I Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
US11096924B2 (en) * 2016-09-07 2021-08-24 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and PGE2 antagonists
EA201990672A1 (ru) * 2016-09-14 2019-08-30 Бэйцзин Ханми Фарм. Ко., Лтд. Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
JP7079773B2 (ja) * 2016-09-14 2022-06-02 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ｐｄ－１抗体及びその使用
CN106350488B (zh) * 2016-09-19 2019-09-27 大连大学 用于治疗肿瘤的pd-1封闭cik的制备方法
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
BR112019004733A2 (pt) 2016-09-19 2019-05-28 Celgene Corp métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
WO2018055503A1 (en) * 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
DK3515938T3 (da) * 2016-09-21 2025-04-07 Cstone Pharmaceuticals Monoklonale antistoffer mod programmeret død 1 (pd-1)
EP4026849A1 (en) 2016-09-26 2022-07-13 Ensemble Group Holdings Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems using a combination of vegfr-3 and pd-1 or pd-l1 inhibitors
EP3504234A4 (en) 2016-09-29 2020-12-02 Beijing Hanmi Pharmaceutical Co., Ltd. CONSTRUCTIONS OF HETERODIMERIC IMMUNOGLOBULINS AND THEIR PREPARATION PROCESSES
EP4541423A3 (en) 2016-10-06 2025-06-25 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
MX386249B (es) * 2016-10-12 2025-03-18 Univ Texas Terapia tusc2 para usarse en el tratamiento de cáncer.
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
CN110099925A (zh) 2016-10-28 2019-08-06 百时美施贵宝公司 使用抗pd-1抗体治疗尿道上皮癌的方法
EP3534950A4 (en) * 2016-11-01 2020-05-06 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
EP4295918A3 (en) * 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SI3535298T1 (sl) 2016-11-02 2022-01-31 Jounce Therapeutics, Inc. Protitelesa proti pd-1 in njihove uporabe
AU2017355446A1 (en) 2016-11-03 2019-05-02 Bristol-Myers Squibb Company Activatable anti-CTLA-4 antibodies and uses thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
ES3008937T3 (en) 2016-11-04 2025-03-25 Aximmune Inc Beta-alethine in combination with immune modulators and uses thereof
SG10201913260VA (en) 2016-11-18 2020-03-30 Beijing Hanmi Pharmaceutical Co Ltd Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US11359018B2 (en) 2016-11-18 2022-06-14 Symphogen A/S Anti-PD-1 antibodies and compositions
KR20190104529A (ko) 2016-12-03 2019-09-10 주노 쎄러퓨티크스 인코퍼레이티드 Car-t 세포의 조절 방법
CN117530948A (zh) 2016-12-05 2024-02-09 G1治疗公司 化疗方案期间免疫反应的保持
AU2017373945B2 (en) 2016-12-07 2025-01-23 Agenus Inc. Antibodies and methods of use thereof
JOP20190133A1 (ar) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
US12168008B2 (en) 2016-12-08 2024-12-17 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
CN108239083B (zh) 2016-12-26 2021-08-17 阿里根公司 芳香烃受体调节剂
KR102679324B1 (ko) * 2017-01-05 2024-06-28 네트리 파르마 네트린-1 간섭 약물과 면역 관문 억제제 약물의 조합 치료
US11591398B2 (en) 2017-01-06 2023-02-28 Crescendo Biologics Limited Single domain antibodies to programmed cell death protein 1 (PD-1)
MX2019008207A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-pd-1.
WO2018132516A1 (en) * 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
US10350266B2 (en) * 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
TWI856437B (zh) 2017-01-20 2024-09-21 法商賽諾菲公司 抗TGF-β抗體及其用途
TW202421659A (zh) 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
CN110177568A (zh) 2017-01-20 2019-08-27 诺华股份有限公司 用于治疗癌症的组合疗法
WO2018133842A1 (zh) * 2017-01-20 2018-07-26 大有华夏生物医药集团有限公司 人程序性死亡受体pd-1的单克隆抗体及其片段
EP3571227A1 (en) 2017-01-20 2019-11-27 Sanofi Anti-tgf-beta antibodies and their use
KR102658660B1 (ko) * 2017-01-23 2024-04-17 크라제 메디컬 씨오 리미티드 Bcma 표적 항체 및 이의 용도
CN108341871A (zh) 2017-01-24 2018-07-31 三生国健药业（上海）股份有限公司 抗pd-1单克隆抗体及其制备方法和应用
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
US11384154B2 (en) 2017-02-06 2022-07-12 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
ES2971448T3 (es) 2017-02-08 2024-06-05 Eisai R&D Man Co Ltd Composición farmacéutica para el tratamiento de tumores
WO2018146612A1 (en) 2017-02-10 2018-08-16 Novartis Ag 1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
IL268479B2 (en) 2017-02-21 2024-06-01 Regeneron Pharma Anti-PD-1 antibodies for the treatment of lung cancer
BR112019017743A2 (pt) 2017-02-28 2020-04-07 Sanofi Sa rna terapêutico
CN110637031B (zh) 2017-03-04 2024-04-16 湘潭腾华生物科技有限公司 程序性死亡蛋白1(pd-1)的重组抗体及其用途
WO2018183928A1 (en) 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor
BR112019016737A2 (pt) 2017-03-31 2020-03-31 Boehringer Ingelheim International Gmbh Terapia anticâncer combinada
SG11201909156RA (en) 2017-04-01 2019-10-30 Beijing hanmi pharm co ltd Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
KR102461885B1 (ko) * 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
EP3606960A1 (en) * 2017-04-03 2020-02-12 Oncologie, Inc. Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
EP4516809A3 (en) 2017-04-05 2025-09-03 F. Hoffmann-La Roche AG Bispecific antibodies specifically binding to pd1 and lag3
WO2018185232A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-1, tim-3, and lag-3
CN114949228A (zh) 2017-04-05 2022-08-30 勃林格殷格翰国际有限公司 抗癌组合疗法
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
US11559537B2 (en) 2017-04-07 2023-01-24 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
WO2018231339A2 (en) * 2017-04-20 2018-12-20 Dana-Farber Cancer Institute, Inc. Anti-phosphotyrosinylated pd-1 antibodies and uses thereof
CN106939049B (zh) * 2017-04-20 2019-10-01 苏州思坦维生物技术股份有限公司 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
KR20200006115A (ko) 2017-05-16 2020-01-17 브리스톨-마이어스 스큅 컴퍼니 항-gitr 효능제 항체에 의한 암의 치료
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
WO2018222722A2 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
CN110691795A (zh) 2017-05-30 2020-01-14 百时美施贵宝公司 包含抗-lag3抗体、pd-1途径抑制剂和免疫治疗剂组合的组合物
IL322104A (en) 2017-05-30 2025-09-01 Bristol Myers Squibb Co Treatment of lag-3 positive tumors
JOP20190279A1 (ar) 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
CA3064331A1 (en) * 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
CA3065929A1 (en) 2017-06-01 2018-12-06 Michael Wayne SAVILLE Bispecific antibodies that bind cd123 and cd3
CN110678483B (zh) 2017-06-01 2023-09-22 百时美施贵宝公司 用抗pd-1抗体治疗肿瘤的方法
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
US11198726B2 (en) 2017-06-02 2021-12-14 Boerhinger Ingelheim International Gmbh Anti-cancer combination therapy
US11413310B2 (en) 2017-06-02 2022-08-16 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
MX2019014577A (es) 2017-06-05 2020-07-29 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y metodos de uso.
EP4461825A3 (en) 2017-06-09 2024-11-20 Providence Health & Services - Oregon Tumor-infiltrating t-cells for use in the treatment of cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
TW201904993A (zh) 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β 結合抗體之用途
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019005635A2 (en) * 2017-06-25 2019-01-03 Systimmune, Inc. ANTI-PD-1 ANTIBODIES AND METHODS OF PREPARATION AND USE
CN110799543A (zh) * 2017-06-26 2020-02-14 百济神州有限公司 肝细胞癌的免疫治疗
US20200223924A1 (en) 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
EP3421494A1 (en) 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
JP7225135B2 (ja) * 2017-07-06 2023-02-20 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための化合物及び方法
US11667714B2 (en) * 2017-07-06 2023-06-06 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
AR112603A1 (es) * 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
NZ761519A (en) 2017-07-14 2023-07-28 Innate Tumor Immunity Inc Nlrp3 modulators
IL319798A (en) * 2017-07-20 2025-05-01 Novartis Ag ANTI-LAG-3 Antibody Dosage Regimens and Their Uses
KR102709265B1 (ko) 2017-07-28 2024-09-23 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
CN111182919B (zh) 2017-08-01 2023-07-07 伊莱利利公司 抗cd137抗体
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
CR20200099A (es) 2017-08-03 2020-07-24 Amgen Inc Muteínas de interleucina 21 y métodos de tratamiento
US10953032B2 (en) 2017-08-31 2021-03-23 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3676278B1 (en) 2017-08-31 2023-04-12 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP7316263B2 (ja) 2017-08-31 2023-07-27 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
US11021540B2 (en) 2017-09-07 2021-06-01 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
US11351163B2 (en) 2017-09-29 2022-06-07 Bristol-Myers Squibb Company Compositions and methods of treating cancer
US20200239559A1 (en) 2017-09-29 2020-07-30 Boehringer Ingelheim International Gmbh Anti igf, anti pd-1, anti-cancer combination therapy
WO2019070908A1 (en) 2017-10-03 2019-04-11 Cedars-Sinai Medical Center METHODS OF TARGETING THE PD1 PATHWAY OF THE IMMUNE CONTROL POINT FOR THE TREATMENT OF PULMONARY FIBROSIS
US10973882B2 (en) 2017-10-03 2021-04-13 Cedars-Sinai Medical Center Methods for reducing severity of pulmonary fibrosis
CN111344297B (zh) 2017-10-10 2023-10-20 百时美施贵宝公司 作为抗癌剂的环二核苷酸
KR20200064132A (ko) 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
US11427610B2 (en) 2017-10-16 2022-08-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
BR112020008638A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
KR20200084880A (ko) 2017-11-06 2020-07-13 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
TW201923089A (zh) 2017-11-06 2019-06-16 美商建南德克公司 癌症之診斷及治療方法
CN112272563A (zh) * 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
KR20200083574A (ko) 2017-11-13 2020-07-08 크레센도 바이오로직스 리미티드 Cd137 및 psma에 결합하는 분자
SG11202003477QA (en) 2017-11-14 2020-05-28 Pfizer Ezh2 inhibitor combination therapies
CN109793892B (zh) * 2017-11-16 2022-07-26 江苏恒瑞医药股份有限公司 一种抗pd-1抗体在制备治疗食管癌的药物中的用途
CN111065411B (zh) * 2017-11-16 2023-03-10 江苏恒瑞医药股份有限公司 Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
US11459322B2 (en) 2017-11-20 2022-10-04 Ariagen, Inc. Indole compounds and their use
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
AU2018375738A1 (en) 2017-11-30 2020-06-11 Novartis Ag BCMA-targeting chimeric antigen receptor, and uses thereof
EP3716991A4 (en) * 2017-12-01 2021-09-08 Soricimed Biopharma Inc. TRPV6 INHIBITORS AND POLYTHERAPIES FOR THE TREATMENT OF CANCERS
TWI763956B (zh) * 2017-12-05 2022-05-11 盧森堡商前胃泌激素及癌症有限公司 治療癌症的抗前胃泌激素抗體與免疫療法之組合療法
MA51184A (fr) 2017-12-15 2020-10-21 Juno Therapeutics Inc Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
WO2019126366A2 (en) * 2017-12-19 2019-06-27 The Johns Hopkins University Baff therapy to promote anti- tumor immunity
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
EP3740507A4 (en) * 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
WO2019143607A1 (en) 2018-01-16 2019-07-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
AU2019210332A1 (en) 2018-01-22 2020-09-10 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP3743076A1 (en) 2018-01-22 2020-12-02 Bristol-Myers Squibb Company Compositions and methods of treating cancer
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
JP2021511793A (ja) 2018-01-31 2021-05-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
CN108314734B (zh) * 2018-01-31 2021-11-05 中国药科大学 抗pd-1单克隆抗体及其应用
KR20200128014A (ko) 2018-01-31 2020-11-11 셀진 코포레이션 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
AU2019215031B2 (en) 2018-01-31 2025-10-09 Novartis Ag Combination therapy using a chimeric antigen receptor
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
WO2019164970A1 (en) * 2018-02-20 2019-08-29 Emory University Hpv proteins, antibodies, and uses in managing abnormal epithelial cell growth
JP7250808B2 (ja) 2018-03-08 2023-04-03 ブリストル－マイヤーズ スクイブ カンパニー 抗がん剤としての環状ジヌクレオチド
WO2019175222A1 (en) 2018-03-13 2019-09-19 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
JP7558563B2 (ja) 2018-03-15 2024-10-01 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
JP2021518380A (ja) * 2018-03-19 2021-08-02 アベオメ コーポレーション プログラム細胞死リガンド１（ｐｄ−ｌ１）に対する高親和性中和モノクローナル抗体、及びその使用
TWI791794B (zh) * 2018-03-20 2023-02-11 瑞士商諾華公司 藥物組合
ES2946343T3 (es) 2018-03-23 2023-07-17 Lilly Co Eli Anticuerpos anti-CD137 para combinación con anticuerpos anti-PD-L1
MA52076A (fr) 2018-03-23 2021-01-27 Lilly Co Eli Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
US20210032344A1 (en) 2018-03-30 2021-02-04 Bristol-Myers Squibb Company Methods of treating tumor
EP3774903A1 (en) 2018-04-04 2021-02-17 Bristol-Myers Squibb Company Anti-cd27 antibodies and uses thereof
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
MA52289A (fr) 2018-04-18 2021-02-24 Xencor Inc Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
KR20210010862A (ko) 2018-04-18 2021-01-28 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
AU2019261582A1 (en) 2018-04-25 2020-11-12 Innate Tumor Immunity, Inc. NLRP3 modulators
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CN112074541A (zh) * 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI806870B (zh) * 2018-05-23 2023-07-01 中國大陸商大有華夏生物醫藥集團有限公司 抗pd-1抗體及其用途
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US12331068B2 (en) 2018-05-31 2025-06-17 Peloton Therapeutics, Inc. Compositions and methods for inhibiting CD73
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2019276656A1 (en) 2018-06-01 2021-01-07 Novartis Ag Dosing of a bispecific antibody that bind CD123 and CD3
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
IL279455B1 (en) 2018-06-20 2025-09-01 Incyte Corp ANTI-PD-1 ANTIBODIES AND THEIR USES
CN112585166A (zh) 2018-06-23 2021-03-30 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法
CN110680919A (zh) * 2018-07-06 2020-01-14 江苏恒瑞医药股份有限公司 Cdk4/6抑制剂联合免疫治疗在制备治疗肿瘤的药物的用途
BR112020026947B1 (pt) 2018-07-10 2022-11-22 Novartis Ag Derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, e composição farmacêutica
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US20200171146A1 (en) 2018-07-18 2020-06-04 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
JP7519985B2 (ja) 2018-07-19 2024-07-22 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 抗ｐｄ－１抗体、投薬量、およびその使用
BR112021000964A2 (pt) 2018-07-25 2021-04-20 Novartis Ag inibidores do inflamassoma de nlrp3
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
JP2021532143A (ja) 2018-07-26 2021-11-25 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 癌の処置のためのｌａｇ−３併用療法
CA3109778A1 (en) 2018-08-16 2020-02-20 Innate Tumor Immunity, Inc. Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
EP3837014B1 (en) 2018-08-16 2022-10-19 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
EP3837015B1 (en) 2018-08-16 2024-02-14 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
WO2020041655A1 (en) 2018-08-24 2020-02-27 Sanofi Therapeutic rna for solid tumor cancers
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
CN112805267B (zh) 2018-09-03 2024-03-08 豪夫迈·罗氏有限公司 用作tead调节剂的甲酰胺和磺酰胺衍生物
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
EP3856782A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
US20220047633A1 (en) 2018-09-28 2022-02-17 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
JP7612571B2 (ja) 2018-10-03 2025-01-14 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
US20210395392A1 (en) 2018-10-09 2021-12-23 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
WO2020079581A1 (en) 2018-10-16 2020-04-23 Novartis Ag Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
EP3866850B1 (en) 2018-10-19 2024-07-24 Bristol-Myers Squibb Company Combination therapy for melanoma
CN112912403A (zh) 2018-10-23 2021-06-04 百时美施贵宝公司 治疗肿瘤的方法
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
TW202021981A (zh) 2018-11-01 2020-06-16 美商奇諾治療有限公司 G蛋白偶合受體c類第5群成員d（gprc5d）特異性嵌合抗原受體
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
PE20211284A1 (es) 2018-11-16 2021-07-19 Bristol Myers Squibb Co Anticuerpos anti-nkg2a y usos de los mismos
BR112021009420A2 (pt) 2018-11-16 2021-11-23 Juno Therapeutics Inc Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
TW202038943A (zh) 2018-11-19 2020-11-01 美商雅里俊公司 治療癌症之方法
EP3886875B1 (en) 2018-11-30 2024-05-08 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
AU2019392090A1 (en) 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
EP3890749B1 (en) 2018-12-04 2025-10-29 Sumitomo Pharma America, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
KR102835299B1 (ko) 2018-12-04 2025-07-18 브리스톨-마이어스 스큅 컴퍼니 다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법
MA54448A (fr) 2018-12-11 2021-10-20 Theravance Biopharma R&D Ip Llc Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
EP3666905A1 (en) 2018-12-11 2020-06-17 Sanofi E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer
US12281125B2 (en) 2018-12-18 2025-04-22 Novartis Ag Rapamycin derivatives
BR112021011874A2 (pt) 2018-12-20 2021-09-08 Novartis Ag Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
WO2020132646A1 (en) 2018-12-20 2020-06-25 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
TW202038932A (zh) * 2018-12-20 2020-11-01 美商拉斐爾製藥公司 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物
CA3119584A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
CA3119582A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1.beta. binding antibodies
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
JOP20210159A1 (ar) 2018-12-21 2023-01-30 Novartis Ag أجسام مضادة لـ pmel17 ومترافقات منها
CN111349162A (zh) * 2018-12-21 2020-06-30 神州细胞工程有限公司 人源化抗pd-1抗体及其用途
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
WO2020136133A1 (en) 2018-12-23 2020-07-02 F. Hoffmann-La Roche Ag Tumor classification based on predicted tumor mutational burden
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
US20220089740A1 (en) 2019-01-11 2022-03-24 Eli Lilly And Company Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer
US12391675B2 (en) 2019-01-14 2025-08-19 Innate Tumor Immunity, Inc. NLRP3 modulators
EP3911417B1 (en) 2019-01-14 2022-10-26 Innate Tumor Immunity, Inc. Heterocyclic nlrp3 modulators , for use in the treatment of cancer
AU2020208193A1 (en) 2019-01-14 2021-07-29 BioNTech SE Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
EP3911642A1 (en) 2019-01-14 2021-11-24 Innate Tumor Immunity, Inc. Nlrp3 modulators
WO2020150113A1 (en) 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
JP2022518236A (ja) 2019-01-21 2022-03-14 サノフイ 進行期固形腫瘍がんに対する治療用ｒｎａおよび抗ｐｄ１抗体
TWI894135B (zh) 2019-01-25 2025-08-21 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
MA54863A (fr) 2019-01-29 2021-12-08 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques du récepteur orphelin-1 de type récepteur à tyrosine kinase (ror1)
JP2022519328A (ja) * 2019-02-08 2022-03-22 マディソン ヴァクシーンズ インコーポレイテッド 癌の治療
AU2020221247B2 (en) 2019-02-12 2024-12-12 Sumitomo Pharma America, Inc. Formulations comprising heterocyclic protein kinase inhibitors
EP3923940B1 (en) 2019-02-12 2025-12-03 Novartis AG Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220088075A1 (en) 2019-02-22 2022-03-24 The Trustees Of The University Of Pennsylvania Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
CA3133460A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
WO2020198676A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
KR20210146348A (ko) 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
EP3956327A1 (en) 2019-04-15 2022-02-23 Ariagen, Inc. Chiral indole compounds and their use
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
EP3956364A1 (en) 2019-04-19 2022-02-23 F. Hoffmann-La Roche AG Anti-mertk antibodies and their methods of use
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
JP2022534889A (ja) 2019-05-24 2022-08-04 ファイザー・インコーポレイテッド Ｃｄｋ阻害剤を使用した組合せ療法
JP2022534967A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 多腫瘍遺伝子シグネチャーおよびその使用
CN114127315A (zh) 2019-05-30 2022-03-01 百时美施贵宝公司 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN112079925B (zh) * 2019-06-13 2025-04-25 上海健信生物医药科技有限公司 靶向lag-3的抗体和双特异性抗体及其用途
KR20220028075A (ko) 2019-07-03 2022-03-08 스미토모 다이니폰 파마 온콜로지, 인크. 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022549273A (ja) 2019-09-22 2022-11-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング
US20220347313A1 (en) 2019-09-25 2022-11-03 Seagen, Inc. Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers
JP7739269B2 (ja) 2019-09-25 2025-09-16 ブリストル－マイヤーズ スクイブ カンパニー がん療法のための複合バイオマーカー
EP4034118A1 (en) * 2019-09-26 2022-08-03 Janssen Pharmaceutica NV Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
AU2020358979A1 (en) 2019-10-03 2022-04-21 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
WO2021076444A1 (en) * 2019-10-14 2021-04-22 Olatec Therapeutics Llc Methods for treating breast cancer
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
JP2022553306A (ja) 2019-10-21 2022-12-22 ノバルティス アーゲー Ｔｉｍ－３阻害剤およびその使用
US20210130438A1 (en) * 2019-10-28 2021-05-06 The Broad Institute, Inc. Pan-cancer t cell exhaustion genes
BR112022007971A8 (pt) 2019-10-29 2023-02-07 Eisai R&D Man Co Ltd Combinação de antagonista do pd-1, inibidor da tirosina quinase vegfr/fgfr/ret e inibidor da cbp/beta-catenina para o tratamento do câncer
JP2022553821A (ja) 2019-11-05 2022-12-26 ブリストル－マイヤーズ スクイブ カンパニー Ｍ－タンパク質アッセイおよびその使用
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
CN115942973A (zh) 2019-11-08 2023-04-07 百时美施贵宝公司 用于黑色素瘤的lag-3拮抗剂疗法
TW202130618A (zh) 2019-11-13 2021-08-16 美商建南德克公司 治療性化合物及使用方法
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
CA3160307A1 (en) 2019-11-22 2021-05-27 Theravance Biopharma R&D Ip, Llc Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
WO2021102343A1 (en) 2019-11-22 2021-05-27 Sumitomo Dainippon Pharma Oncology, Inc. Solid dose pharmaceutical composition
CN115066259A (zh) 2019-12-09 2022-09-16 思进公司 使用liv1-adc和pd-1拮抗剂的组合疗法
US20230089255A1 (en) 2019-12-19 2023-03-23 Bristol-Myers Squibb Company Combinations of dgk inhibitors and checkpoint antagonists
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
JP7573622B2 (ja) 2020-01-10 2024-10-25 イネイト・テューマー・イミュニティ・インコーポレイテッド Ｎｌｒｐ３モジュレーター
TW202128131A (zh) * 2020-01-17 2021-08-01 大陸商信達生物制藥(蘇州)有限公司 重組抗程式性細胞死亡受體1和抗分化抗原簇137雙特異性抗體製劑及其用途
KR20220128389A (ko) 2020-01-17 2022-09-20 노파르티스 아게 골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물
EP4097130A1 (en) 2020-01-30 2022-12-07 Ona Therapeutics S.L. Combination therapy for treatment of cancer and cancer metastasis
CN115397459A (zh) 2020-01-31 2022-11-25 基因泰克公司 用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
JP2023514152A (ja) 2020-02-06 2023-04-05 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－１０およびその使用
MX2022010515A (es) 2020-02-28 2022-11-14 Tallac Therapeutics Inc Conjugacion mediada por transglutaminasa.
TW202146452A (zh) 2020-02-28 2021-12-16 瑞士商諾華公司 結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥
IL295626A (en) 2020-02-28 2022-10-01 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor
US20230089536A1 (en) 2020-03-06 2023-03-23 Celgene Quanticel Research, Inc. Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
MX2022011050A (es) 2020-03-06 2022-12-15 Ona Therapeutics S L Anticuerpos anti-cd36 y su uso para tratar cancer.
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
MX2022011296A (es) * 2020-03-12 2023-02-09 Personal Genome Diagnostics Inc Distintivos de inestabilidad de microsatélites.
KR20220157446A (ko) 2020-03-23 2022-11-29 브리스톨-마이어스 스큅 컴퍼니 암을 치료하기 위한 항-ccr8 항체
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2021203131A1 (en) 2020-03-31 2021-10-07 Theravance Biopharma R&D Ip, Llc Substituted pyrimidines and methods of use
KR20220161395A (ko) * 2020-04-01 2022-12-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 중간엽 줄기 세포-유래된 암 세포 및 중간엽 줄기 세포 연관된 질환을 표적화하는 이뮤노테라노스틱 작용제
WO2021207689A2 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
WO2021226984A1 (zh) * 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
CN116249555A (zh) 2020-05-19 2023-06-09 勃林格殷格翰国际有限公司 用于癌症治疗的结合分子
MX2022014974A (es) 2020-05-26 2023-01-11 Boehringer Ingelheim Int Anticuerpos anti-pd-1.
CN111537726A (zh) * 2020-05-29 2020-08-14 武汉大学 高效定量检测细胞外囊泡中pd-l1水平的方法、elisa试剂盒及使用方法
KR20230019152A (ko) 2020-06-02 2023-02-07 아르커스 바이오사이언시즈 인코포레이티드 Tigit에 대한 항체
AU2021285068A1 (en) 2020-06-03 2023-01-19 Boehringer Ingelheim International Gmbh Recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein
TW202214623A (zh) 2020-06-10 2022-04-16 美商施萬生物製藥研發 Ip有限責任公司 結晶型alk5抑制劑及其用途
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
PE20230839A1 (es) 2020-06-22 2023-05-19 Ngm Biopharmaceuticals Inc Agentes de union a lair-1 y metodos para su uso
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR20230058442A (ko) 2020-08-28 2023-05-03 브리스톨-마이어스 스큅 컴퍼니 간세포성 암종에 대한 lag-3 길항제 요법
BR112023003553A2 (pt) 2020-08-31 2023-04-04 Bristol Myers Squibb Co Assinatura de localização celular e imunoterapia
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
JP2023540490A (ja) 2020-09-02 2023-09-25 ファーマブシン インコーポレイテッド がん患者を治療するためのｐｄ－１拮抗薬及びｖｅｇｆｒ－２拮抗薬の併用療法
TW202227126A (zh) 2020-09-14 2022-07-16 德商百靈佳殷格翰國際股份有限公司 異源初免加強疫苗
CN116472290A (zh) 2020-09-24 2023-07-21 默沙东有限责任公司 程序性死亡受体1（pd-1）抗体和透明质酸酶变体及其片段的稳定制剂及其使用方法
CN111920948B (zh) * 2020-09-25 2021-02-02 安可瑞(山西)生物细胞有限公司 包含免疫细胞的药物组合物用于治疗癌症
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
WO2022076596A1 (en) 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
TW202233671A (zh) 2020-10-20 2022-09-01 美商建南德克公司 Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
JP2023548051A (ja) 2020-10-23 2023-11-15 ブリストル－マイヤーズ スクイブ カンパニー 肺がんのためのｌａｇ－３アンタゴニスト療法
JP2023549678A (ja) 2020-10-28 2023-11-29 イケナ オンコロジー， インコーポレイテッド ＡＨＲ阻害剤のＰＤｘ阻害剤またはドキソルビシンとの組み合わせ
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
TW202432189A (zh) 2020-11-04 2024-08-16 美商建南德克公司 以抗 cd20/抗 cd3 雙特異性抗體和抗 cd79b 抗體藥物結合物治療的給藥方法
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
KR20230117162A9 (ko) 2020-12-02 2024-03-21 제넨테크, 인크. 신보조 및 보조 요로상피 암종 요법을 위한 방법 및 조성물
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
EP4566674A3 (en) 2020-12-28 2025-08-06 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
JP7623497B2 (ja) 2020-12-31 2025-01-28 サノフイ ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ
WO2022156773A1 (en) * 2021-01-21 2022-07-28 Biocytogen Pharmaceuticals (Beijing) Co., Ltd Protein complexes targeting il12 pathway
WO2022157715A1 (en) 2021-01-22 2022-07-28 Dcprime B.V. Methods of tumor vaccination
JP2024505049A (ja) 2021-01-29 2024-02-02 ノバルティス アーゲー 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
AU2022246593A1 (en) 2021-03-29 2023-10-12 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
MX2023012277A (es) 2021-04-16 2023-12-07 Novartis Ag Conjugados anticuerpo-fármaco y métodos para fabricar los mismos.
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
WO2022232503A1 (en) 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CA3218786A1 (en) 2021-05-25 2022-12-01 Lifei HOU C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
PE20240587A1 (es) 2021-05-26 2024-03-21 Novartis Ag Analogos de triazolo-pirimidina para el tratamiento de enfermedades relacionadas con la inhibicion de la helicasa recq del sindrome de werner (wrn)
TW202313679A (zh) 2021-06-03 2023-04-01 美商欣爍克斯公司 包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
TWI833242B (zh) * 2021-06-11 2024-02-21 大陸商廣東菲鵬製藥股份有限公司 抗pd-1人源化抗體或其抗原結合片段、編碼其的核酸、包含其的載體、細胞和藥物組合物及其用途
EP4355363A1 (en) 2021-06-18 2024-04-24 Genzyme Corporation Anti-tgf-beta antibody formulations and their use
TW202309078A (zh) 2021-07-02 2023-03-01 美商建南德克公司 治療癌症之方法及組成物
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
WO2023010094A2 (en) 2021-07-28 2023-02-02 Genentech, Inc. Methods and compositions for treating cancer
CN117715936A (zh) 2021-07-28 2024-03-15 豪夫迈·罗氏有限公司 用于治疗癌症的方法和组合物
US20250206836A1 (en) 2021-07-30 2025-06-26 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
EP4413040A1 (en) 2021-10-06 2024-08-14 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
KR20240099362A (ko) 2021-10-29 2024-06-28 브리스톨-마이어스 스큅 컴퍼니 혈액암에 대한 lag-3 길항제 요법
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
US20250009916A1 (en) 2021-11-12 2025-01-09 Novartis Ag Combination therapy for treating lung cancer
CN114167256B (zh) * 2021-11-19 2024-05-07 上海御渡半导体科技有限公司 一种基于数字tdr技术的模拟测量装置和测量方法
TW202332429A (zh) 2021-11-24 2023-08-16 美商建南德克公司 治療性化合物及其使用方法
TW202340212A (zh) 2021-11-24 2023-10-16 美商建南德克公司 治療性化合物及其使用方法
WO2023122573A1 (en) 2021-12-20 2023-06-29 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
JP2025503962A (ja) 2022-01-26 2025-02-06 ブリストル－マイヤーズ スクイブ カンパニー 肝細胞がんのための併用療法
IL314524A (en) 2022-01-28 2024-09-01 Georgiamune Inc Antibodies to programmed cell death protein 1 that are agonists for PD-1
US20250179174A1 (en) 2022-02-25 2025-06-05 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
AU2023230110A1 (en) 2022-03-08 2024-10-24 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
JPWO2023176881A1 (enExample) 2022-03-16 2023-09-21
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
JP2025509749A (ja) 2022-03-18 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー ポリペプチドの単離方法
CA3246312A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
CN116925223A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pd-1单克隆抗体及其衍生物和用途
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
WO2023196964A1 (en) 2022-04-08 2023-10-12 Bristol-Myers Squibb Company Machine learning identification, classification, and quantification of tertiary lymphoid structures
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
AU2022458320A1 (en) 2022-05-11 2024-11-28 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CA3253038A1 (en) 2022-05-12 2023-11-16 Genmab A/S LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY
CA3257280A1 (en) 2022-05-25 2023-11-30 Msd International Gmbh COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
CN119365495A (zh) 2022-05-27 2025-01-24 赛诺菲 与NKp46和BCMA变体结合的具有Fc工程化的自然杀伤（NK）细胞接合物
US20250332252A1 (en) 2022-06-02 2025-10-30 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
KR20250022049A (ko) 2022-06-07 2025-02-14 제넨테크, 인크. 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
US12487299B2 (en) 2022-06-20 2025-12-02 Shanghai United Imaging Healthcare Co., Ltd. Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices
EP4543923A1 (en) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
CA3261147A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4310197A1 (en) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
CN119923267A (zh) 2022-07-27 2025-05-02 阿斯利康(瑞典)有限公司 表达白介素-12的重组病毒与pd-1/pd-l1抑制剂的组合
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
CN120153254A (zh) 2022-09-01 2025-06-13 基因泰克公司 膀胱癌的治疗和诊断方法
WO2024069009A1 (en) 2022-09-30 2024-04-04 Alentis Therapeutics Ag Treatment of drug-resistant hepatocellular carcinoma
EP4599088A1 (en) 2022-10-05 2025-08-13 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
TW202417450A (zh) 2022-10-12 2024-05-01 瑞士商諾華公司 三環化合物及其用途
KR20250093336A (ko) 2022-10-25 2025-06-24 제넨테크, 인크. 다발성 골수종에 대한 치료 및 진단 방법
EP4619104A1 (en) 2022-11-16 2025-09-24 Novartis AG Bicyclic heterocycles and their use as wrn inhibitors
US20250340648A1 (en) 2022-12-01 2025-11-06 Medimmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
WO2024115725A1 (en) 2022-12-01 2024-06-06 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
AR131320A1 (es) 2022-12-13 2025-03-05 Juno Therapeutics Inc Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
KR20250120305A (ko) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
EP4637807A2 (en) 2022-12-20 2025-10-29 Genentech Inc. Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
KR20250123912A (ko) 2022-12-21 2025-08-18 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 병용 요법
WO2024150177A1 (en) 2023-01-11 2024-07-18 Advesya Treatment methods for solid tumors
TW202444764A (zh) 2023-01-20 2024-11-16 德商百靈佳殷格翰國際股份有限公司 IL-12 Fc融合蛋白
EP4658310A1 (en) 2023-01-30 2025-12-10 Kymab Limited Antibodies
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
EP4669429A1 (en) 2023-02-23 2025-12-31 Imcheck Therapeutics COMBINATION OF BTN3A ACTIVATING ANTIBODIES AND IMMUNE CHECKPOINT INHIBITORS
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
WO2024228167A1 (en) 2023-05-03 2024-11-07 Iox Therapeutics Inc. Inkt cell modulator liposomal compositions and methods of use
AU2024270495A1 (en) 2023-05-05 2025-10-09 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer
AU2024271605A1 (en) 2023-05-12 2025-11-13 BioNTech SE Antibodies capable of binding to ox40, variants thereof and uses thereof
WO2024236048A1 (en) 2023-05-16 2024-11-21 Nh Theraguix Combination therapy for treating tumors with radiotherapy
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024261239A1 (en) 2023-06-23 2024-12-26 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
WO2025024257A1 (en) 2023-07-21 2025-01-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025049277A1 (en) 2023-08-25 2025-03-06 Genentech, Inc. Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025085404A1 (en) 2023-10-16 2025-04-24 Genentech, Inc. Diagnostic and therapeutic methods for treating lung cancer
WO2025114541A1 (en) 2023-11-30 2025-06-05 Genmab A/S Antibodies capable of binding to ox40 in combination therapy
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025132695A1 (en) 2023-12-19 2025-06-26 Boehringer Ingelheim International Gmbh Recombinant rhabdovirus encoding for a gasdermin
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025155607A1 (en) 2024-01-16 2025-07-24 Genentech, Inc. Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine
WO2025174933A1 (en) 2024-02-14 2025-08-21 Genentech, Inc. Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
EP4658320A1 (en) 2024-02-27 2025-12-10 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025232879A1 (en) 2024-05-10 2025-11-13 Cytocares (Shanghai) Inc. Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056875A1 (en) * 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US20110123550A1 (en) * 2008-07-04 2011-05-26 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
US20110271358A1 (en) * 2008-09-26 2011-11-03 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
CN103242448A (zh) * 2013-05-27 2013-08-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用

Family Cites Families (525)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0067069A1 (en) 1981-06-10 1982-12-15 Harold Swallow Invalid chairs
US4433059A (en) 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
EP0090505B1 (en) 1982-03-03 1990-08-08 Genentech, Inc. Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
WO1988008135A1 (en) 1987-04-10 1988-10-20 Xoma Corporation Human monoclonal antibodies binding determinants of gram negative bacteria
DE3884470T2 (de) 1987-06-17 1994-03-10 Sandoz Ag Cyclosporine und deren Benutzung als Arzneimittel.
JPH021556A (ja) 1988-06-09 1990-01-05 Snow Brand Milk Prod Co Ltd ハイブリッド抗体及びその作製方法
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2636953B1 (fr) 1988-09-26 1990-12-14 Roussy Inst Gustave Nouveaux polypeptides produits par des lymphocytes humains, genes codant pour ces polypeptides et applications pharmaceutiques et biologiques
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0546091B1 (en) 1990-08-29 2007-01-24 Pharming Intellectual Property BV Homologous recombination in mammalian cells
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US6596536B1 (en) 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
ATE338134T1 (de) 1991-02-08 2006-09-15 Aventis Pharma Sa Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungen
EP0528007A1 (fr) 1991-02-12 1993-02-24 Roussel Uclaf SEQUENCES NUCLEOTIDIQUES CODANT POUR DES REGIONS VARIABLES DE CHAINES $g(b) DES RECEPTEURS DES LYMPHOCYTES T HUMAINS, SEGMENTS PEPTIDIQUES CORRESPONDANTS ET LES APPLICATIONS DIAGNOSTIQUES ET THERAPEUTIQUES
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU661854B2 (en) 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5910573A (en) 1992-01-23 1999-06-08 Merck Patent Gesellschaft Mit Beschrankter Haftung Monomeric and dimeric antibody-fragment fusion proteins
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
AU675223B2 (en) 1992-05-08 1997-01-30 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
DE69334287D1 (de) 1992-09-25 2009-07-09 Avipep Pty Ltd Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
GB9323648D0 (en) 1992-11-23 1994-01-05 Zeneca Ltd Proteins
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
IL108501A (en) 1994-01-31 1998-10-30 Mor Research Applic Ltd Antibodies and pharmaceutical compositions containing them
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
KR100257466B1 (ko) 1994-05-06 2000-07-01 레지날드 쇼트버그 에스. 안토니우스-소도 Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법 치료 조성물, 항-이디오타입 항체
EP0787185A2 (en) 1994-10-20 1997-08-06 MorphoSys AG Targeted hetero-association of recombinant proteins to multi-functional complexes
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
DE69633175T2 (de) 1995-05-23 2005-08-11 Morphosys Ag Multimere proteine
WO1997003695A1 (en) 1995-07-21 1997-02-06 Applied Research Systems Ars Holding N.V. Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EP0773288A3 (en) 1995-08-29 1997-07-09 Kirin Brewery Chimera animal and its method of manufacture
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
JP2000508892A (ja) 1996-04-04 2000-07-18 ユニリーバー・ナームローゼ・ベンノートシャープ 多価および多特異的抗原結合タンパク
TW533205B (en) 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
CA2263129C (en) 1996-08-16 2007-01-09 Schering Corporation Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
DE69735502T2 (de) 1996-11-28 2006-12-14 Applied Research Systems Ars Holding N.V. Mutanten des lag-3 proteins, ihre expression und verwendung
EP1695985B1 (en) 1997-04-07 2011-03-09 Genentech, Inc. Methods for forming humanised antibodies by random mutagenesis
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
SI1325932T1 (enExample) 1997-04-07 2005-08-31 Genentech Inc
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO1998056906A1 (en) 1997-06-11 1998-12-17 Thoegersen Hans Christian Trimerising module
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
AU1102399A (en) 1997-10-21 1999-05-10 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
CN1203178C (zh) 1997-10-27 2005-05-25 尤尼利弗公司 多价抗原结合蛋白
WO1999037791A1 (en) 1998-01-23 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Multipurpose antibody derivatives
EP1053321A1 (en) 1998-02-09 2000-11-22 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
WO1999052552A1 (en) 1998-04-15 1999-10-21 Brigham & Women's Hospital, Inc. T cell inhibitory receptor compositions and uses thereof
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
JP5341287B2 (ja) 1998-12-03 2013-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｃｔｌａ−４遮断薬を用いる自己抗原に対するｔ細胞の刺激
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
FR2794025A1 (fr) 1999-05-25 2000-12-01 Transgene Sa Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
AU5309600A (en) 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
ES2295040T3 (es) 1999-07-12 2008-04-16 Genentech, Inc. Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
IL148021A0 (en) 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
WO2001090192A2 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
ATE385504T1 (de) 2000-06-06 2008-02-15 Bristol Myers Squibb Co Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung
NZ522700A (en) 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
WO2002000730A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: novel pd-1 ligands and uses therefor
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
JP2004523205A (ja) 2000-07-25 2004-08-05 イムノメディクス， インコーポレイテッド 多価標的結合タンパク質
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20020107363A1 (en) 2000-09-20 2002-08-08 Amgen, Inc. B7-Like molecules and uses thereof
JP2004511503A (ja) 2000-10-20 2004-04-15 大野　典也 疾患を治療するための融合細胞およびサイトカイン組成物
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
EP2351838A1 (en) 2000-10-20 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Crosslinking agonistic antibodies
US7414171B2 (en) 2000-11-15 2008-08-19 Ono Pharmaceutical Co., Ltd. PD-1-lacking mouse and use thereof
JP2002194491A (ja) 2000-12-27 2002-07-10 Daido Steel Co Ltd ばね用鋼材
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CN1277843C (zh) 2001-02-22 2006-10-04 巴斯德研究院 分枝杆菌比较基因组学作为鉴定分枝杆菌病的诊断、预防或治疗靶的工具
WO2002072635A2 (en) 2001-03-13 2002-09-19 University College London Specific binding members
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
EP1383912A4 (en) 2001-04-02 2007-11-28 Wyeth Corp PD-1, B7-4 RECEPTOR, AND ITS USES
US20020146753A1 (en) 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
US6727072B2 (en) 2001-05-01 2004-04-27 Dako Corporation EGF-r detection kit
US6592849B2 (en) 2001-06-21 2003-07-15 Colgate Palmolive Company Chewing gum to control malodorous breath
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
JP4572276B2 (ja) 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
JP2003029846A (ja) 2001-07-11 2003-01-31 Sanyo Electric Co Ltd 流量調整器および流量調整器を備えた飲料供給装置
EP1445264B1 (en) 2001-07-31 2011-09-14 Ono Pharmaceutical Co., Ltd. Substance specific to pd-1
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
EP1295895B1 (en) 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
ES2336433T3 (es) 2001-09-19 2010-04-13 Alexion Pharmaceuticals, Inc. Moldes modififcados mediante ingenieria genetica y su uso en amplificacion de cebador unico.
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
CN1582150B (zh) 2001-10-30 2011-09-07 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
AU2002357072A1 (en) 2001-12-07 2003-06-23 Centocor, Inc. Pseudo-antibody constructs
EP4091631A1 (en) 2002-01-30 2022-11-23 The Brigham and Women's Hospital, Inc. A tim-3 binding molecule for use in the treatment of a disease
WO2003064383A2 (en) 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
TWI350285B (en) 2002-03-13 2011-10-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
AU2003227504A1 (en) 2002-04-15 2003-10-27 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
US20070185017A1 (en) 2002-10-29 2007-08-09 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2345885T3 (es) 2002-11-15 2010-10-05 Novartis Vaccines And Diagnostics, Inc. Metodos para prevenir y tratar metastasis de cancer y perdida de hueso asociada con la metastasis de cancer.
US7449300B2 (en) 2002-11-21 2008-11-11 Mayo Foundation For Medical Education And Research Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
EP1611112B1 (en) 2003-02-11 2012-08-22 Vernalis (Cambridge) Limited Isoxazole compounds as inhibitors of heat shock proteins
US20050009136A1 (en) 2003-02-19 2005-01-13 Dyax Corporation PAPP-A ligands
EP1897548B2 (en) 2003-02-28 2024-05-22 The Johns Hopkins University T cell regulation
GB0305702D0 (en) 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
EP1618181B1 (en) 2003-04-22 2014-10-15 IBC Pharmaceuticals Polyvalent protein complex
JP4638876B2 (ja) 2003-05-23 2011-02-23 ワイス Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
AU2004252170B2 (en) 2003-06-27 2011-01-27 Biogen Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
WO2005007190A1 (en) 2003-07-11 2005-01-27 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
KR20060089732A (ko) 2003-10-03 2006-08-09 브라이엄 앤드 위민즈 하스피틀 Ｔｉｍ-3 리간드 및 그의 방법
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
CA2541360A1 (en) 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
EP1682103A1 (en) 2003-10-27 2006-07-26 Novartis AG Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
JP2007518399A (ja) 2003-12-02 2007-07-12 ジェンザイム コーポレイション 肺癌を診断および治療する組成物並びに方法
WO2005062916A2 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US7626030B2 (en) 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
US8383575B2 (en) 2004-01-30 2013-02-26 Paul Scherrer Institut (DI)barnase-barstar complexes
US20050276756A1 (en) 2004-03-24 2005-12-15 Hoo William S Compositions as adjuvants to improve immune responses to vaccines and methods of use
JP4633788B2 (ja) 2004-04-13 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー 抗ｐ−セレクチン抗体
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
RS50569B (sr) 2004-06-11 2010-05-07 Japan Tobacco Inc. Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
CA2572098C (en) 2004-06-30 2015-01-27 Mayo Foundation For Medical Education And Research B7-dc binding antibody
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
KR20070038556A (ko) 2004-07-20 2007-04-10 심포젠 에이/에스 항-ｒｈｅｓｕｓ ｄ 재조합 폴리클로날 항체 및 이의 제조방법
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
WO2006021955A2 (en) 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
TWI380996B (zh) * 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
MX2007003533A (es) 2004-10-01 2007-05-23 Medarex Inc Metodos de tratar linfomas cd30 positivas.
SI1810026T1 (en) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 and PD-1 in the treatment of renal cell carcinoma
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
AU2006232920B2 (en) 2005-04-06 2011-09-29 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US9296816B2 (en) 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
MX349137B (es) 2005-06-08 2017-07-13 Dana-Farber Cancer Inst Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
AU2006261127B2 (en) * 2005-06-17 2012-03-15 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
JP4557003B2 (ja) 2005-07-01 2010-10-06 株式会社村田製作所 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
PT3248613T (pt) 2005-07-18 2022-03-16 Seagen Inc Conjugados de ligante de fármaco e beta-glucuronida
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
RU2515108C2 (ru) 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
EP1757622B1 (en) 2005-08-26 2009-12-23 PLS Design GmbH Bivalent IgY antibody constructs for diagnostic and therapeutic applications
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
US8623356B2 (en) 2005-11-29 2014-01-07 The University Of Sydney Demibodies: dimerization-activated therapeutic agents
JP2009518320A (ja) 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
UA116187C2 (uk) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
US20090215084A1 (en) 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX2008010561A (es) 2006-02-15 2009-03-02 Imclone Systems Inc Anticuerpos funcionales.
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
US8946391B2 (en) 2006-03-24 2015-02-03 The Regents Of The University Of California Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
EP4218801A3 (en) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
EP2027153B1 (en) 2006-05-25 2014-04-30 Bayer Intellectual Property GmbH Dimeric molecular complexes
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
EP2078732B1 (en) 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
HRP20140081T1 (hr) 2006-08-18 2014-03-28 Novartis Ag Prlr-specifiäśna antitijela i njihova uporaba
AU2007286808B2 (en) 2006-08-21 2012-12-06 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
JP2010504356A (ja) 2006-09-20 2010-02-12 ザ ジョンズ ホプキンス ユニバーシティー 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法
DK3284825T3 (da) 2006-11-02 2021-05-25 Biomolecular Holdings Llc Fremgangsmåder til at fremstille hybride polypeptider med bevægelige dele
WO2008060617A2 (en) 2006-11-15 2008-05-22 The Brigham And Women's Hospital, Inc. Therapeutic uses of tim-3 modulators
AU2007323725B2 (en) 2006-11-22 2014-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
WO2008067283A2 (en) 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use
EP2311807B1 (en) 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
WO2008073687A2 (en) 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2102241A2 (en) 2006-12-15 2009-09-23 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
EP2133365B1 (en) * 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
EP2139924B1 (en) 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
US20080260738A1 (en) 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
US8153595B2 (en) 2007-07-13 2012-04-10 The Johns Hopkins University B7-DC variants immunogenic compositions and methods of use thereof
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CA2694488A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
WO2009024531A1 (en) 2007-08-17 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
US8425897B2 (en) 2007-08-30 2013-04-23 Immutep S.A. Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
EP2195342A1 (en) 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
MX2010005783A (es) 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
EA023031B1 (ru) 2007-11-30 2016-04-29 Глаксо Груп Лимитед Антиген-связывающая конструкция и ее применение
AR069803A1 (es) 2007-12-19 2010-02-17 Genentech Inc 5- anilinoimiazopiridinas y metodos de uso
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
HUE050958T2 (hu) 2008-01-15 2021-01-28 Univ Leland Stanford Junior Akut mieloid leukémia õssejtek markerei
US20110059106A1 (en) 2008-01-29 2011-03-10 Brigham And Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
BRPI0907718A2 (pt) 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
WO2009114335A2 (en) * 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
US8709715B2 (en) 2008-03-26 2014-04-29 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
MX393622B (es) 2008-05-21 2025-03-24 Incyte Corp Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
JP5351254B2 (ja) 2008-05-23 2013-11-27 ノバルティス アーゲー キノキサリン−およびキノリン−カルボキシアミド誘導体
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
CA2729810A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Tgf-.beta. antagonist multi-target binding proteins
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
WO2010006086A2 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8575427B2 (en) 2008-08-12 2013-11-05 The United States Of America As Represented By The Secretary Of Agriculture Chorismate mutase gene from the potato cyst nematode Globodera rostochiensis
BRPI0917791B1 (pt) 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
BRPI0918268B1 (pt) 2008-09-02 2021-08-03 Novartis Ag Derivados de picolinamida, seu uso, e composição farmacêutica
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
US8586023B2 (en) 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
EP2342228B1 (en) 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN102753193A (zh) 2008-10-31 2012-10-24 比奥根艾迪克Ma公司 Light靶向分子及其用途
WO2010056735A1 (en) 2008-11-11 2010-05-20 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity
CN102227221A (zh) 2008-11-28 2011-10-26 诺瓦提斯公司 包含hsp90抑制剂和mtor抑制剂的药物组合
JP5520961B2 (ja) 2008-11-28 2014-06-11 エモリー ユニバーシティ 感染症および腫瘍を処置するための方法
JP2012510821A (ja) 2008-12-04 2012-05-17 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
JP5569946B2 (ja) 2009-01-26 2014-08-13 国立大学法人 岡山大学 免疫抑制剤および自己免疫疾患の予防および治療剤
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
WO2010102278A1 (en) 2009-03-06 2010-09-10 President And Fellows Of Harvard College Methods and compositions for the generation and maintenance of regulatory t cells
EP2412825B8 (en) 2009-03-24 2018-01-10 Riken Leukemia stem cell markers
ES2571235T3 (es) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
LT2990421T (lt) 2009-04-30 2018-04-25 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anti-ceacam1 antikūnai ir jų panaudojimo būdai
BRPI1012195A2 (pt) 2009-05-01 2018-04-24 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
MX2011011669A (es) 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las misma.
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
KR101360725B1 (ko) 2009-06-26 2014-02-07 노파르티스 아게 Ｃｙｐ17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체
DK2769737T3 (en) 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
NZ598929A (en) 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
IN2012DN01920A (enExample) 2009-09-03 2015-07-24 Schering Corp
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
AU2010303149B2 (en) 2009-09-30 2016-08-04 Board Of Regents, The University Of Texas System Combination immunotherapy for the treatment of cancer
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
MX343747B (es) 2009-11-24 2016-11-22 Medimmune Ltd Agentes de union diana contra b7-h1.
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2011090762A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
WO2011100841A1 (en) 2010-02-16 2011-08-25 Valorisation-Recherche, Limited Partnership Pd-1 modulation and uses thereof for modulating hiv replication
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CA3253628A1 (en) 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2796181C (en) 2010-04-20 2023-01-03 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
RU2624027C2 (ru) 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
SG185502A1 (en) 2010-05-14 2012-12-28 Abbvie Inc Il-1 binding proteins
JP6158511B2 (ja) 2010-06-11 2017-07-05 協和発酵キリン株式会社 抗ｔｉｍ−３抗体
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012018538A2 (en) 2010-07-26 2012-02-09 Schering Corporation Bioassays for determining pd-1 modulation
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PH12013500333A1 (en) 2010-08-20 2013-04-22 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
BR112013010857A2 (pt) 2010-11-02 2016-09-13 Abbott Laboratoires imonoglubulinas de duplo domínio variável e usos das mesmas
UY33707A (es) 2010-11-04 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP6014596B2 (ja) 2010-11-09 2016-10-25 メディミューン，エルエルシー 均一コンジュゲーションのための抗体足場
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US8814630B2 (en) 2011-01-04 2014-08-26 Carl T. Rittberger PVC beehive
CN103649117B (zh) 2011-02-04 2016-09-14 霍夫曼-拉罗奇有限公司 Fc变体及其生成方法
DK2691112T3 (en) 2011-03-31 2018-07-30 Merck Sharp & Dohme STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS
PT2699264T (pt) 2011-04-20 2018-05-23 Medimmune Llc Anticorpos e outras moléculas que ligam b7-h1 e pd-1
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
WO2012177788A1 (en) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
AU2012273182A1 (en) 2011-06-21 2014-01-16 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
WO2013043647A1 (en) 2011-09-19 2013-03-28 The Johns Hopkins University Cancer immunotherapy
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013060867A2 (en) 2011-10-27 2013-05-02 Genmab A/S Production of heterodimeric proteins
AU2012332840A1 (en) 2011-10-31 2014-05-15 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
GB201120527D0 (en) 2011-11-29 2012-01-11 Ucl Business Plc Method
CA2892371C (en) 2011-12-01 2021-01-19 The Brigham And Women's Hospital, Inc. Anti-ceacam1 recombinant antibodies for cancer therapy
CN102492038B (zh) 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
CN104379574B (zh) 2012-05-15 2017-03-01 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
EA201492007A1 (ru) 2012-05-15 2015-03-31 Новартис Аг Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
AU2013261129B2 (en) 2012-05-15 2016-05-12 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
PE20210667A1 (es) 2012-05-15 2021-04-05 Novartis Ag Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
EA037351B8 (ru) * 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN104508149A (zh) 2012-07-27 2015-04-08 诺华股份有限公司 对jak/stat抑制剂治疗响应的预测
EP2879498A4 (en) 2012-07-30 2016-03-30 Alex Wah Hin Yeung BY TREATMENT OF AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE TEST MODULE DEVELOPED TUMOR SPECIFIC LIVING AND IN VIVO CANCER VACCINE SYSTEM
EP2879709B1 (en) 2012-07-31 2020-01-08 The Brigham and Women's Hospital, Inc. Modulation of the immune response
EP2890715B1 (en) 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
US20150250837A1 (en) 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
EP2904011B1 (en) 2012-10-02 2017-08-23 Bristol-Myers Squibb Company Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
CN104994873B (zh) 2012-10-04 2017-12-22 达纳－法伯癌症研究所公司 人单克隆抗‑pd‑l1抗体和使用方法
AU2013343425A1 (en) 2012-11-08 2015-06-11 Novartis Ag Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
JP2016501221A (ja) 2012-11-28 2016-01-18 ノバルティス アーゲー 併用療法
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
TW201514188A (zh) 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
WO2014165082A2 (en) 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
IL240838B (en) 2013-03-15 2022-09-01 Glaxosmithkline Ip Dev Ltd Anti-3–lag binding proteins
EP2981821B2 (en) 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
ES2845609T3 (es) 2013-05-02 2021-07-27 Anaptysbio Inc Anticuerpos dirigidos contra muerte programada-1 (PD-1)
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
BR112015028326A8 (pt) 2013-06-03 2018-01-23 Novartis Ag combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica
MX384142B (es) 2013-07-16 2025-03-14 Genentech Inc Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
EP3035964B1 (en) 2013-08-20 2020-09-23 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
KR102661249B1 (ko) 2013-09-11 2024-04-25 메디뮨 리미티드 종양 치료용 항-ｂ7-ｈ1 항체
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
US10081681B2 (en) 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP4285928A3 (en) 2013-09-27 2024-03-13 F. Hoffmann-La Roche AG Anti-pdl1 antibody formulations
US10202454B2 (en) 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
BR112016010166A2 (pt) 2013-11-11 2017-12-05 Armo Biosciences Inc métodos para usar interleucina-10 para tratar doenças e distúrbios
WO2015081158A1 (en) 2013-11-26 2015-06-04 Bristol-Myers Squibb Company Method of treating hiv by disrupting pd-1/pd-l1 signaling
WO2015088847A1 (en) 2013-12-11 2015-06-18 Glaxosmithkline Llc Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
EP3527587A1 (en) 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP4070818A3 (en) 2014-01-06 2023-01-11 The Trustees of the University of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
WO2015109124A2 (en) 2014-01-15 2015-07-23 Kadmon Corporation, Llc Immunomodulatory agents
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
RS62788B1 (sr) 2014-01-28 2022-02-28 Bristol Myers Squibb Co Anti-lag-3 antitela za lečenje hematoloških maligniteta
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
SG11201606428UA (en) 2014-02-04 2016-09-29 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
WO2015120198A1 (en) 2014-02-05 2015-08-13 Cedars-Sinai Medical Center Methods and compositions for treating cancer and infectious diseases
DK3105246T3 (da) 2014-02-10 2021-06-14 Merck Patent Gmbh Målrettet TGF-beta-inhibering
US20170088626A1 (en) 2014-03-05 2017-03-30 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
CA2949121A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
ES2753360T3 (es) 2014-05-29 2020-04-08 Spring Bioscience Corp Anticuerpos contra PD-L1 y usos de los mismos
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
DK3183268T3 (da) 2014-08-19 2020-05-11 Univ Pennsylvania Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
IL251464B2 (en) 2014-10-29 2023-03-01 Five Prime Therapeutics Inc Combination therapy for cancer
US20170320954A1 (en) 2014-11-17 2017-11-09 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
FI3277321T3 (fi) 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HUE059218T2 (hu) 2015-04-08 2022-11-28 Novartis Ag CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
WO2017011580A2 (en) * 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
CN108136003A (zh) 2015-07-29 2018-06-08 诺华股份有限公司 抗pd-1和抗m-csf抗体在癌症治疗中的联合应用
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
RU2018105846A (ru) 2015-07-29 2019-08-28 Новартис Аг Комбинация антагониста pd-1 с ингибитором egfr
RS59688B1 (sr) * 2015-08-11 2020-01-31 Novartis Ag 5-bromo-2,6-di-(1h-pirazol-1-il)pirimidin-4-amin za upotrebu pri lečenju raka
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CN108430503A (zh) 2015-10-28 2018-08-21 艾杜罗生物科技公司 用于激活“干扰素基因刺激物”依赖性信号传导的组合物和方法
BR112018010211A2 (pt) 2015-12-07 2019-02-05 Merck Patent Gmbh formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP4643874A2 (en) 2015-12-22 2025-11-05 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
IL260218B2 (en) 2016-01-11 2023-04-01 Novartis Ag Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
WO2017189433A1 (en) 2016-04-25 2017-11-02 Medimmune, Llc Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN110214150A (zh) 2016-07-28 2019-09-06 诺华股份有限公司 嵌合抗原受体和pd-1抑制剂的组合疗法
CN110741429A (zh) 2017-04-10 2020-01-31 韩厚华 基于带有展示装置家具的家居环境调节系统及控制方法
IL322104A (en) 2017-05-30 2025-09-01 Bristol Myers Squibb Co Treatment of lag-3 positive tumors
CA3066054A1 (en) 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer therapy and kit therefor
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
US20200223924A1 (en) 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
IL319798A (en) 2017-07-20 2025-05-01 Novartis Ag ANTI-LAG-3 Antibody Dosage Regimens and Their Uses
WO2019018640A1 (en) 2017-07-21 2019-01-24 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-GITREN ANTIBODIES AND USES THEREOF
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CA3119584A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
TW202124443A (zh) 2019-09-16 2021-07-01 瑞士商諾華公司 高親和力的、配位基阻斷性、人源化的抗T細胞免疫球蛋白結構域和黏蛋白結構域3(TIM-3)IgG4抗體用於治療骨髓纖維化之用途
JP2022553306A (ja) 2019-10-21 2022-12-22 ノバルティス アーゲー Ｔｉｍ－３阻害剤およびその使用
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
KR20220128389A (ko) 2020-01-17 2022-09-20 노파르티스 아게 골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056875A1 (en) * 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US20110123550A1 (en) * 2008-07-04 2011-05-26 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
US20110271358A1 (en) * 2008-09-26 2011-11-03 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
CN103242448A (zh) * 2013-05-27 2013-08-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用

Also Published As

Publication number Publication date
JP2018162306A (ja) 2018-10-18
TN2016000272A1 (en) 2017-10-06
SI3097121T1 (sl) 2019-05-31
CY1121542T1 (el) 2020-07-31
JP2017506067A (ja) 2017-03-02
US20180155427A1 (en) 2018-06-07
JP2019193628A (ja) 2019-11-07
EP3097121A1 (en) 2016-11-30
CA2935423C (en) 2023-11-07
EP3514179A1 (en) 2019-07-24
TW202045549A (zh) 2020-12-16
KR102357621B1 (ko) 2022-02-04
EP3097121B1 (en) 2018-12-19
PE20170255A1 (es) 2017-03-22
MX2016009616A (es) 2017-05-09
UA122479C2 (uk) 2020-11-25
MY184757A (en) 2021-04-20
WO2015112900A1 (en) 2015-07-30
RS58535B1 (sr) 2019-04-30
US11827704B2 (en) 2023-11-28
HK1225747B (en) 2017-09-15
US9815898B2 (en) 2017-11-14
IL278803A (en) 2021-01-31
JOP20200094A1 (ar) 2017-06-16
US20250066479A1 (en) 2025-02-27
CA2935423A1 (en) 2015-07-30
ME03366B (me) 2019-10-20
MX375683B (es) 2025-03-06
IL246382A0 (en) 2016-08-31
CL2016001723A1 (es) 2017-04-28
SG11201604939SA (en) 2016-08-30
US20170247456A1 (en) 2017-08-31
AU2015209145B2 (en) 2020-08-13
HRP20190516T1 (hr) 2019-05-03
NZ721678A (en) 2023-04-28
EA201691488A1 (ru) 2017-02-28
EP3514179B1 (en) 2022-11-02
JP6521986B2 (ja) 2019-05-29
CN106103485A (zh) 2016-11-09
US20200339689A1 (en) 2020-10-29
MX2020001909A (es) 2020-07-13
HUE043363T2 (hu) 2019-08-28
BR112016015677A2 (pt) 2017-10-03
WO2015112900A8 (en) 2016-08-18
CN111909269A (zh) 2020-11-10
TW202237655A (zh) 2022-10-01
KR20160110995A (ko) 2016-09-23
SG10201900002QA (en) 2019-02-27
US10752687B2 (en) 2020-08-25
ES2716685T3 (es) 2019-06-14
JP6518370B2 (ja) 2019-05-22
LT3097121T (lt) 2019-05-10
US9683048B2 (en) 2017-06-20
US20150210769A1 (en) 2015-07-30
CN106103485B (zh) 2020-06-30
PL3097121T3 (pl) 2019-06-28
CN111909270A (zh) 2020-11-10
TW201536808A (zh) 2015-10-01
JO3560B1 (ar) 2020-07-05
PH12016501456A1 (en) 2016-08-22
UY35967A (es) 2015-08-31
AU2015209145A1 (en) 2016-07-07
ECSP16068976A (es) 2019-07-31
AU2020204366A1 (en) 2020-07-23
DK3097121T3 (en) 2019-04-15
PT3097121T (pt) 2019-04-01

Similar Documents

Publication Publication Date Title
US20250066479A1 (en) Antibody molecules to pd-1 and uses thereof
TWI697500B (zh) 針對ｌａｇ-３之抗體分子及其用途
TWI716362B (zh) 針對ｐｄ－ｌ１之抗體分子及其用途
HK40007040A (en) Antibody molecules to pd-1 and uses thereof
HK40031258A (en) Antibody molecules to lag-3 and uses thereof
HK1225747A1 (en) Antibody molecules to pd-1 and uses thereof
HK1229355B (en) Antibody molecules to lag-3 and uses thereof
HK1229355A1 (en) Antibody molecules to lag-3 and uses thereof